Release Date: December 22, 2025
Expiration Date: December 22, 2026
Activity Overview
This online, on-demand virtual symposium brings together renowned experts in acute lymphocytic leukemia (ALL). In this educational program, these experts discuss the integration of T-cell therapies, including CAR T-cell therapies, immunotherapies, and bispecific antibodies, as well as best practices for sequencing CD19-targeting therapies. By placing the data in a clinical context, oncology practitioners can assess and apply these findings to their clinical practice and ultimately improve care for their patients with ALL.
This educational activity is an archive of the live symposium held on December 18, 2025.
Target Audience
This educational activity is directed toward academic and community-based oncologists, advanced practice providers, oncology nurses, and other health care providers involved in the treatment of patients with ALL.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Evaluate recent clinical trial data on approved and emerging therapeutic strategies for acute lymphocytic leukemia (ALL), with a focus on advances in bispecific antibodies and CAR-T cell therapies
- Interpret the latest guidelines and evidence for biomarker-driven strategies to stratify risk and guide the use of bispecific and CAR-T cell therapies in patients with ALL
- Describe best practices for mitigating and managing treatment-related adverse events in patients with ALL
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here